AIMT 's oral peanut allergy treatment will likely be the first choice for ages 4-17 It will also be first to market and enjoy market preference for most adults until and if ANAB's treatment comes to market FDA approval could come in 2019 Competitor ANAB's treatment targets adults and is 6 years away from coming to market Competitor DBVT 's patch is best suited for infants and pre-schoolers and has poorer overall efficacy.